Elevian
Menlo Park, US · Founded 2017 · Delaware corporation · 5 employees on LinkedIn · 10 known investors
Find your way into Elevian
601 people in our graph share verified history with the Elevian team — schools, employers, funds. One of them is your warm intro.
Alex Chachavaunlockedknows Mark Allen · together at YPO (overlapped)
×2knows the team · via Columbia University
×6knows the team · via YPO
×3knows the team · via UCLA
Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation. The protein has also shown regenerative effects in preclinical models of aging-related cardiovascular, neurological, metabolic, pulmonary, renal, and skeletal muscle conditions.
Founders & leadership
Elevian was founded in 2017 by Mark Allen.
MA
Mark AlleninCo-Founder and CEO2017–2024Dr. Mark Allen earned his M.D. from UCLA and co-founded Elevian with Harvard scientists to develop biotherapeutics targeting aging-related diseases; he previously founded Corticon, an AI decision-support platform acquired by Progress.
CJ
Casey J McGlynnNamed on SEC filing
SG
Sebastian GiwainFounding Executive Chairman / Since 2021, Chairman2017–2023Director at Ossium Health
LA
Luis AlvarezNamed on SEC filing
DM
Daniel MarshakNamed on SEC filing
Board
SF
Suzanne FletcherBoard director
Investors · 10
Bold Capital PartnersSanta Monica
Thynk Capitalvia Jim Plante · inferred
BOLD Capitalreported · 2 sourcesSanta Monica
For Good Venturesreported · 2 sources
Lauder Partnersreported · 2 sourcesLos Altos
Prime Movers Labreported · 3 sourcesJackson · $2M – $30Mvia Caleb Bell III · board
WTIreported · 2 sourcesPortola Valley
Also in the syndicate · 3
Kizoo VenturesLongevity FundSavEarth Fund
Reported raises · per SEC filings
Form D private placements$38M disclosed across 2 rounds · 2020–2021
▶$22.7MraisedSep 2021 · 29 investors · OtherRule 506(b)
▶$22.7MraisedSep 2021 · 29 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- J. Casey McGlynnExecutive Officer
- Mark AllenExecutive Officer, Director
- Daniel MarshakDirector
- Brandon SimmonsDirector
- Caleb BellDirector
- Sebastian GiwaExecutive Officer, Director
- Offering amount
- $42.7M
- Amount sold
- $22.7M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$15.3MraisedJul 2020 · 68 investors · OtherRule 506(b)
▶$15.3MraisedJul 2020 · 68 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Suzanne FletcherDirector
- Casey J McGlynnExecutive Officer
- Mark AllenExecutive Officer, Director
- Sebastian GiwaExecutive Officer, Director
- Luis AlvarezExecutive Officer
- Daniel MarshakDirector
- Offering amount
- $15.4M
- Amount sold
- $15.3M
- Minimum investment
- $1
- First sale
- Jul 2020
- Incorporated
- Corporation, California, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
IQVIA27 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Bioworld20 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Elevian for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Elevian do?
- Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation. The protein has also shown regenerative effects in preclinical models of aging-related cardiovascular, neurological, metabolic, pulmonary, renal, and skeletal muscle conditions.
- Who founded Elevian?
- Elevian was founded by Mark Allen in 2017.
- Who are Elevian's investors?
- Elevian's investors include Bold Capital Partners, Thynk Capital, BOLD Capital, For Good Ventures, Lauder Partners, Prime Movers Lab, WTI.
- How much funding has Elevian raised?
- Elevian has disclosed $38M raised across 2 rounds.
- Where is Elevian headquartered?
- Elevian is headquartered in Menlo Park, US.